Sanofi SA (SNY) on Tuesday said the European Commission has approved Cenrifki for the treatment of secondary progressive multiple sclerosis (SPMS) in adults who have not experienced relapses in the past two years.
The approval was supported by results from the Phase 3 HERCULES study, which showed that Cenrifki significantly delayed disability progression in patients with non-relapsing SPMS. Data from the Phase 3 GEMINI 1 and GEMINI 2 studies in relapsing multiple sclerosis also supported the approval.
Sanofi said it expects to launch Cenrifki in Germany later this year.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.